TY - JOUR
T1 - In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives
AU - Kudo, Kei
AU - Hashimoto, Takuya
AU - Hashimoto, Junko
AU - Kozone, Ikuko
AU - Kagaya, Noritaka
AU - Ueoka, Reiko
AU - Nishimura, Takehiro
AU - Komatsu, Mamoru
AU - Suenaga, Hikaru
AU - Ikeda, Haruo
AU - Shin-ya, Kazuo
N1 - Funding Information:
This work was supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP19ae0101045 for K.S.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - One major bottleneck in natural product drug development is derivatization, which is pivotal for fine tuning lead compounds. A promising solution is modifying the biosynthetic machineries of middle molecules such as macrolides. Although intense studies have established various methodologies for protein engineering of type I modular polyketide synthase(s) (PKSs), the accurate targeting of desired regions in the PKS gene is still challenging due to the high sequence similarity between its modules. Here, we report an innovative technique that adapts in vitro Cas9 reaction and Gibson assembly to edit a target region of the type I modular PKS gene. Proof-of-concept experiments using rapamycin PKS as a template show that heterologous expression of edited biosynthetic gene clusters produced almost all the desired derivatives. Our results are consistent with the promiscuity of modular PKS and thus, our technique will provide a platform to generate rationally designed natural product derivatives for future drug development.
AB - One major bottleneck in natural product drug development is derivatization, which is pivotal for fine tuning lead compounds. A promising solution is modifying the biosynthetic machineries of middle molecules such as macrolides. Although intense studies have established various methodologies for protein engineering of type I modular polyketide synthase(s) (PKSs), the accurate targeting of desired regions in the PKS gene is still challenging due to the high sequence similarity between its modules. Here, we report an innovative technique that adapts in vitro Cas9 reaction and Gibson assembly to edit a target region of the type I modular PKS gene. Proof-of-concept experiments using rapamycin PKS as a template show that heterologous expression of edited biosynthetic gene clusters produced almost all the desired derivatives. Our results are consistent with the promiscuity of modular PKS and thus, our technique will provide a platform to generate rationally designed natural product derivatives for future drug development.
UR - http://www.scopus.com/inward/record.url?scp=85089359842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089359842&partnerID=8YFLogxK
U2 - 10.1038/s41467-020-17769-2
DO - 10.1038/s41467-020-17769-2
M3 - Article
C2 - 32782248
AN - SCOPUS:85089359842
SN - 2041-1723
VL - 11
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4022
ER -